Inclusion Criteria:
  1. Subject voluntarily gives informed consent to participate in the study.
  2. Subject participated in Study RIN-PH-304 and completed all scheduled study visits.
  3. Women of childbearing potential (defined as less than 1 year post-menopausal and not surgically sterile) must be practicing abstinence or using 2 highly effective methods of contraception (defined as a method of birth control that results in a low failure rate, [less than 1% per year], such as approved hormonal contraceptives, barrier methods [such as condom or diaphragm] used with a spermicide, or an intrauterine device). Subject must have a negative urine pregnancy test at the Enrollment Visit.
  4. Males with a partner of childbearing potential must agree to use a barrier method (condom) with a spermicide for the duration of treatment and for at least 48 hours after discontinuing study drug.
Exclusion Criteria:
  1. The subject is pregnant or lactating.
  2. The subject was prematurely discontinued from Study RIN-PH-304.
  3. The subject is intolerant to prostanoid therapy.
  4. The subject is scheduled to receive another investigational drug, device, or therapy during the course of this study.
  5. Any other clinically significant illness or abnormal laboratory value(s) that, in the opinion of the Investigator, might adversely affect the interpretation of the study data.